Curated CRC research — accessible, accurate, actionable

The CRC Digest

Monday, August 24, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ● REGULATORY

  FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults

  The FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 and older at average risk, based on data from the PREEMPT CRC trial. (The ASCO Post)

• ◆ TRIAL DATA

  Adding Chemotherapy to Immunotherapy May Extend Survival in MSI-H Metastatic CRC

  The phase III NRG-GI004/SWOG S1610 COMMIT trial found that combining mFOLFOX6, bevacizumab, and atezolizumab may prolong progression-free survival over atezolizumab alone in first-line treatment of mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. (The ASCO Post)

• ▸ TREATMENT

  Bispecific Antibody EMB-01 Shows Activity in Heavily Pretreated Metastatic CRC

  A phase Ib/II study (NCT05176665) of EMB-01, a novel EGFR × c-MET bispecific antibody, enrolled 52 patients with heavily pretreated metastatic colorectal cancer. EMB-01 was administered at 1600 mg intravenously weekly, with primary endpoints of safety and tolerability in phase Ib, and antitumor activity in phase II. (Clinical Cancer Research)

• ▪ SCREENING

  Risk-Adapted Screening Strategy Shows Promise for Early-Onset CRC

  A new study found that implementing a RAP-based risk-adapted screening strategy enables personalized screening initiation, with benefits comparable to those observed in the current 50-54-year age group. (Cancer Science)

Research continues to advance screening options and personalized treatment strategies for colorectal cancer patients.